Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?

Table 3 Quality of life survey compliance

Questionnaire part (total number of questions)	Number of questions answered	% completion
B1- EORTC QLQ-30 & PR25 (55)
	55	13 · 1
	54	35 · 4
	53	5 · 8
	47-52	41 · 5
	<43	3 · 9
B2- Depression Anxiety & Stress Scales (42)
	42	92 · 2
	41	5 · 3
	40	1 · 0
	<31	1 · 5

Part B1 exclusions-
The question regarding the use of an incontinence aid (Question number 38) was removed from the analysis as only 29 · 6 % of participants have completed this question. However, urinary symptom score assessed without question 38 was significantly higher among incontinence aid users compared to non-users [median 35·4 ((75th percentile 56·6 %) vs20·8 (75th percentile 33·3 %) with a p < 0·001 ]. Therefore, removal of question 38 has no significant impact in our assessment
Question numbers 52–55 related to those who were sexually active over the 4 weeks prior to completion of the questionnaire were also removed from analysis, as only 59 · 7 % have answered these questions. However, sexual interest score assessed between those that recorded sexual activity was significantly higher than those that have not recorded sexual activity [median 50 (75th percentile 66·6 %) vs 16·7 (75th percentile 33·3 %) with a p < 0·001]. Therefore, removal of questions 52–55 has no significant impact in our assessment

ISSN: 1471-2490